-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KL3Fgby7GredxPZaPSkPLq5bjP4g0qmD2Myt6HzBfsPbjmthlLDs27nMVWUcmdno uG4ROLqIwJbOyWy4SYTR6Q== 0001169232-07-004570.txt : 20071207 0001169232-07-004570.hdr.sgml : 20071207 20071207161002 ACCESSION NUMBER: 0001169232-07-004570 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20071205 FILED AS OF DATE: 20071207 DATE AS OF CHANGE: 20071207 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CARACO PHARMACEUTICAL LABORATORIES LTD CENTRAL INDEX KEY: 0000887708 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 382505723 STATE OF INCORPORATION: MI FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: 1150 ELIJAH MCCOY DR CITY: DETROIT STATE: MI ZIP: 48202 BUSINESS PHONE: 3138718400 MAIL ADDRESS: STREET 1: 1150 ELIJAH MCCOY DRIVE CITY: DETROIT STATE: MI ZIP: 48202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SHANGHVI DILIP S CENTRAL INDEX KEY: 0001249644 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31773 FILM NUMBER: 071292750 BUSINESS ADDRESS: STREET 1: 1150 ELIJAH MCCOY CITY: DETROIT STATE: MI ZIP: 48202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SUN PHARMA GLOBAL INC CENTRAL INDEX KEY: 0001197088 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31773 FILM NUMBER: 071292751 BUSINESS ADDRESS: STREET 1: SPARC AKOTA ROAD CITY: VADODARA STATE: A1 ZIP: 00000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SUN PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0001197089 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31773 FILM NUMBER: 071292752 BUSINESS ADDRESS: STREET 1: SPARC AKOTA ROAD CITY: VADODARA STATE: K7 ZIP: 390020 BUSINESS PHONE: 01191228212128 4 1 d07-73153_ex.xml X0202 4 2007-12-05 0 0000887708 CARACO PHARMACEUTICAL LABORATORIES LTD CPD 0001197089 SUN PHARMACEUTICAL INDUSTRIES LTD 17/B MAHAL INDUSTRIAL ESTATE MAHAKALI CAVES ROAD ADHERI (EAST) MUMBAI 400 093 K7 INDIA 0 0 1 0 0001197088 SUN PHARMA GLOBAL INC INTERNATIONAL TRUST BUILDING P.O. BOX 659, ROAD TOWN TORTOLA D8 VIRGIN ISLANDS, BRITISH 0 0 1 0 0001249644 SHANGHVI DILIP S 17/B MAHAL INDUSTRIAL ESTATE MAHAKALI CAVES ROAD ANDHERI (EAST), MUMBAI 400 093 K7 INDIA 1 1 0 0 (Non Executive) Chairman Common Stock 2007-12-07 4 C 0 1088000 A 12838014 I See Footnote Common Stock 8382666 D Series B. Preferred Stock 0 2007-12-07 4 C 0 544000 0 D 2007-11-24 Common Stock 544000 9248000 I See Footnote Series B. Preferred Stock 0 2007-12-07 4 C 0 544000 0 D 2007-12-06 Common Stock 544000 8704000 I See Footnote Series B. Preferred Stock 0 2007-12-05 4 J 0 544000 A 2010-12-05 Common Stock 544000 9248000 I See Footnote The Series B preferred shares converted into Common Stock on a one-to-one basis and had no expiration date. These shares are owned directly by Sun Global, Inc., which is a wholly-owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun"). Dilip S. Shanghvi is the controlling shareholder of Sun. Sun and Mr. Shanghvi disclaim beneficial ownership of the reported shares except to the extent of their respective pecuniary interests therein. These shares are owned directly by Sun. Dilip S. Shanghvi is the controlling shareholder of Sun. Mr. Shanghvi disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein. The Series B preferred shares are convertible into common stock after three years (or immediately upon a change in control) on a one-to-one basis. Sun Global earns 544,000 shares of Series B Preferred Stock for each technology transferred to Caraco of a generic drug by Sun Global when such drug passes its bioequivalency studies. In the event of the dissolution of Caraco, such shares have a preference equal to the value attributed to them on the dates on which they were earned. The value attributed as of December 5, 2007 was $10.81 per share. The shares of Series B remain outstanding until such time as they are converted to common stock. /s/ Dilip S. Shanghvi, Chairman and Managing Director of Sun Pharmaceutical Industries Limited 2007-12-07 /s/ Dilip S. Shanghvi, Director of Sun Pharma Global, Inc. 2007-12-07 /s/ Dilip S. Shanghvi 2007-12-07 -----END PRIVACY-ENHANCED MESSAGE-----